Sharon Shacham - Nov 14, 2022 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
Director
Signature
/s/ Rasmus Holm-Jorgensen, Attorney-in-Fact
Stock symbol
ACRV
Transactions as of
Nov 14, 2022
Transactions value $
$0
Form type
4
Date filed
11/16/2022, 06:28 PM
Previous filing
Nov 9, 2022
Next filing
Jun 24, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRV Stock Option (Right to Buy) Award $0 +35.2K $0.00 35.2K Nov 14, 2022 Common Stock 35.2K $12.50 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall vest in 36 equal monthly installments starting on October 12, 2022 ("Vesting Commencement Date"), such that all shares are fully vested on the third anniversary of the Vesting Commencement Date, in each case subject to the Reporting Person's continuous service through each such vesting date.